212061-28-4

Basic information

• Product Name: 2'-O-[2-[(diMethylaMino)oxy]ethyl]-5-Methyl-uridine
• Synonyms: 2'-O-[2-[(diMethylaMino)oxy]ethyl]-5-Methyl-uridine
• CAS NO: 212061-28-4
• Molecular Formula: C₁₄H₂₃N₃O₇
• Molecular Weight: 345.34832
• Mol File: 212061-28-4.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2'-O-[2-[(diMethylaMino)oxy]ethyl]-5-Methyl-uridine(CAS DataBase Reference)
• NIST Chemistry Reference: 2'-O-[2-[(diMethylaMino)oxy]ethyl]-5-Methyl-uridine(212061-28-4)
• EPA Substance Registry System: 2'-O-[2-[(diMethylaMino)oxy]ethyl]-5-Methyl-uridine(212061-28-4)

Safety Data

• Hazardous Substances Data: 212061-28-4(Hazardous Substances Data)

Upstream product

• 22423-26-3 O-2,2'-cyclo-5-methyluridine 
• 1704-62-7 1-O-Dimethylaminoethyl-ethylenglykol 

Downstream Products

• 212061-29-5 5'-O-(4,4'-dimethoxytrityl)-2'-O-(2-N,N-dimethylaminooxyethyl)-5-methyluridine 
• 1463-10-1 5-Methyluridine 

Relevant articles and documents

EFFECTS OF APOLIPOPROTEIN B INHIBITION ON GENE EXPRESSION PROFILES IN ANIMALS

Antisense compounds, compositions and methods are provided for modulating the expression of apolipoprotein B. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding apolipoprotein B. Methods of using these compounds for modulation of apolipoprotein B expression and for treatment of diseases associated with expression of apolipoprotein B are provided. Methods are provided for modulating the expression of genes involved in lipid metabolism, useful in the treatment of conditions associated with cardiovascular risk. Antisense oligonucleotides targeted to apolipoprotein B reduce the level of apolipoprotein B mRNA, lower serum cholesterol and shift liver gene expression profiles from those of an obese animal towards those of a lean animal. Further provided are methods for improving the cardiovascular risk of a subject through antisense inhibition of apolipoprotein B. Also provided are methods for employing antisense oligonucleotides targeted to apolipoprotein B to modulate a cellular pathway or metabolic process.

Antisense modulation of TFAP2C expression

Antisense compounds, compositions and methods are provided for modulating the expression of TFAP2C. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding TFAP2C. Methods of using these compounds for modulation of TFAP2C expression and for treatment of diseases associated with expression of TFAP2C are provided.

Antisense modulation of P2X4 expression

Antisense compounds, compositions and methods are provided for modulating the expression of P2X4. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding P2X4. Methods of using these compounds for modulation of P2X4 expression and for treatment of diseases associated with expression of P2X4 are provided.